glm101
Recombinant proteinexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Nov 30, 2022 (NCT05549219)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
GMPPB substrate
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06892288 | Phase 2/Phase 3 (Phase 3) | Jul 9, 2025 | Glycomine, Inc. |
| NCT06657859 | Phase 2 | Sep 30, 2024 | Glycomine, Inc. |
| NCT05549219 | Phase 2 | Nov 30, 2022 | Glycomine, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Glycomine, Inc. | For profit | 3 | 3 | 2 | 2022 |
1 organizations
Page 1 / 1